LY2835219 (Cas No. 1231929-97-7)
Product Quick Detail
- Cas No.
- 1231929-97-7
- Formula
- C27H32F2N8
- M.Wt
- 506.59
- Purity
- 98%
- Solubility
- DMSO
- Synonyms
- Abemaciclib; CDK4/6 dual inhibitor; LY-2835219 free base
- Packaging
- Fluorinated Bottles
- Delivery
- 7 Days
Specifications
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic
activity. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase
transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain
types of cancer, causes cell cycle deregulation.
- Country: China (Mainland)
- Business Type:
- Market:European Union,Americas
- Founded Year:2009
- Address:武汉东湖高新区长城科技园光谷精工D栋402室
- Contact:Rosie Liu
